
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is currently focused on developing Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa), which have shown potential to treat various cancers, viral diseases, and immune-deficiency disorders. The company's recent Q4 2025 results showed a net loss of $4.2 million, but with multiple shots on goal in collaboration with major cancer research centers in the US and promising key clinical data expected in Q1 and Q3 2027, the company's current valuation appears attractive. However, risks to be aware of include the changing macroeconomic factors and competition in the biotech industry.
Bears say
AIM ImmunoTech is a pharmaceutical company that is facing financial struggles as it has minimal revenue and a history of net losses. With only $6 million in cash and $4 million in debt in Q1, the company has turned to selling stock in order to raise funds. Although it has a promising focus on pancreatic cancer treatment, the uncertainty of clinical trials and limited financial resources make this stock a risky investment.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares